Intra-articular electrotransfer of mouse soluble tumour necrosis factor receptor in a murine model of rheumatoid arthritis

The Journal of Gene Medicine
Anne DenysMarie-Christophe Boissier

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation and destruction of the joints. In the collagen-induced arthritis mouse model of RA, we developed a nonviral gene therapy method designed to block in situ the main cytokine tumour necrosis factor (TNF)-alpha Electrotransfer was used to deliver a plasmid encoding extracellular domain of mouse soluble TNF-alpha receptor type I fused to the Fc fragment of mouse immunoglobulin (Ig)G1 (pTNFR-Is) corresponding to a dimeric TNF-alpha soluble receptor fusion protein (mTNFR-Is/Ig). Delivery of the plasmid into the knees at symptom onset improved the histological inflammation and destruction not only at the knees, but also at the ankles, indicating a local and a regional therapeutic effect. The plasmid was detected in synovial membrane and meniscus specimens from the injected joints. In the synovial membrane, 15 days post-injection, interleukin (IL)-17 and TNF-alpha mRNAs expression were increased, whereas IL-10 mRNA was unchanged. However, the empty plasmid exerted a pro-inflammatory effect 30 days post-injection. These data indicate that local nonviral gene therapy against TNF-alpha is effective, although further work is needed to decrease plasmid induced...Continue Reading

References

Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·J KollsB Beutler
Jan 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K N KimR Hirsch
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·N S YewS H Cheng
Feb 15, 2001·Arthritis Research·W B van den Berg
Mar 13, 2001·Annual Review of Immunology·M Feldmann, R N Maini
Jun 11, 2002·Biochemical and Biophysical Research Communications·Suzuyo OhashiOsam Mazda
Nov 20, 2002·The Journal of Gene Medicine·Natacha BessisMarie-Christophe Boissier
Dec 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·James M K ChanSharon M Wahl
May 2, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Laurent GrossinPierre Gillet
Dec 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Hélène Le BuanecMarie-Christophe Boissier
Apr 7, 2007·Current Opinion in Rheumatology·Myew-Ling Toh, Pierre Miossec
Apr 29, 2008·Nature Biotechnology·Stephen C HydeDeborah R Gill
May 20, 2008·Annals of Medicine·Laure DelavalléeMarie-Christophe Boissier
May 31, 2008·Arthritis Research & Therapy·Christopher H EvansPaul D Robbins
Jun 24, 2008·Joint, Bone, Spine : Revue Du Rhumatisme·Marie-Christophe BoissierNatacha Bessis
Nov 5, 2008·The Journal of Clinical Investigation·Fionula M Brennan, Iain B McInnes
Nov 7, 2008·Human Gene Therapy·Peter WehlingChristopher H Evans
Jun 23, 2009·Joint, Bone, Spine : Revue Du Rhumatisme·Paola CaramaschiDomenico Biasi

❮ Previous
Next ❯

Citations

Feb 10, 2016·Journal of Cellular and Molecular Medicine·Anne DenysLuca Semerano
Feb 22, 2012·Immunology Letters·Tamás Németh, Attila Mócsai

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.